Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kamath, K.
Right arrow Articles by Jordan, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamath, K.
Right arrow Articles by Jordan, M. A.
Mol Cancer Ther. 2006;5:2225-2233
© 2006 American Association for Cancer Research

Research Articles: Therapeutics

2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules

Kathy Kamath1, Tatiana Okouneva1, Gary Larson1, Dulal Panda2, Leslie Wilson1 and Mary Ann Jordan1

1 Department of Molecular, Cellular, and Developmental Biology and the Neuroscience Research Institute, University of California, Santa Barbara, California and 2 Indian Institute of Technology Bombay, Mumbai, India

Requests for reprints: Kathy Kamath, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Bio II Room 3106, Santa Barbara, CA 93106. Phone: 805-893-8057. E-mail: kamath{at}lifesci.ucsb.edu

2-Methoxyestradiol (2ME2), a metabolite of estradiol-17ß, is a novel antimitotic and antiangiogenic drug candidate in phase I and II clinical trials for the treatment of a broad range of tumor types. 2ME2 binds to tubulin at or near the colchicine site and inhibits the polymerization of tubulin in vitro, suggesting that it may work by interfering with normal microtubule function. However, the role of microtubule depolymerization in its antitumor mechanism of action has been controversial. To determine the mechanism by which 2ME2 induces mitotic arrest, we analyzed its effects on microtubule polymerization in vitro and its effects on dynamic instability both in vitro and in living MCF7 cells. In vitro, 2ME2 (5–100 µmol/L) inhibited assembly of purified tubulin in a concentration-dependent manner, with maximal inhibition (60%) at 200 µmol/L 2ME2. However, with microtubule-associated protein–containing microtubules, significantly higher 2ME2 concentrations were required to depolymerize microtubules, and polymer mass was reduced by only 13% at 500 µmol/L 2ME2. In vitro, dynamic instability was inhibited at lower concentrations. Specifically, 4 µmol/L 2ME2 reduced the mean growth rate by 17% and dynamicity by 27%. In living interphase MCF7 cells at the IC50 for mitotic arrest (1.2 µmol/L), 2ME2 significantly suppressed the mean microtubule growth rate, duration and length, and the overall dynamicity, consistent with its effects in vitro, and without any observable depolymerization of microtubules. Taken together, the results suggest that the major mechanism of mitotic arrest at the lowest effective concentrations of 2ME2 is suppression of microtubule dynamics rather than microtubule depolymerization per se. [Mol Cancer Ther 2006;5(9):2225–33]


Grant support: Grants CA57291 (M.A. Jordan), NS13560 (L. Wilson), and fellowship SB050106 (K. Kamath).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

3 K. Kamath, L. Wilson, and M.A. Jordan, unpublished results.

4 T. LaVallee, EntreMed, Inc., personal communication.

Received 2/28/06; revised 7/14/06; accepted 7/26/06.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
P. G. Morris and M. N. Fornier
Microtubule Active Agents: Beyond the Taxane Frontier
Clin. Cancer Res., November 15, 2008; 14(22): 7167 - 7172.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Y.E. Liaw, N. K. Salam, M. J. McKay, A. M. Cunningham, D. E. Hibbs, and M. Kavallaris
Class I {beta}-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Mol. Cancer Ther., October 1, 2008; 7(10): 3150 - 3159.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. V. Rajkumar, P. G. Richardson, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. Schlossman, C. F. Sidor, K. C. Anderson, and M. A. Gertz
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Clin. Cancer Res., October 15, 2007; 13(20): 6162 - 6167.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.